ALK and non-small cell lung carcinoma: The FDA, on the basis of results from the PROFILE 1001 trial, has also granted Crizotinib, a type 1a MET-TKI, which also inhibits the ROS1 and ALK kinases, a breakthrough therapy designation for the treatment of patients with metastatic NSCLC with METex14 alterations progressing after platinum-based chemotherapy [13].